Agents that block
advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: A novel therapeutic strategy for diabetic vascular complications.
The skin has inherent repair processes to offset damage from internal and external factors such as sunlight, air pollution, and
advanced glycation end products (AGEs).
These substances are currently called
advanced glycation end products (AGEs) (1, 2).
Advanced glycation end products (AGE) have been implicated in diabetes-related complications.
AGEs:
Advanced glycation end products ACE: Angiotensin converting enzyme CML: Carboxymethyl-lysine MetS: Metabolic syndrome sRAGE: Soluble receptor for
advanced glycation end products esRAGE: Endogenous secretory RAGE MG: Methylglyoxal ELISA: Enzyme-linked immunosorbent assay.
Soluble receptor for
advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation," The FASEB Journal, vol.
Genotoxicity of
advanced glycation end products in mammalian cells.
Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease.
The receptor of
advanced glycation end products pathway has been extensively studied in the context of diabetic complications and has been shown to constitute a link between hyperglycemia and microvascular damage (5).
The researchers determined the AGE content by determining levels of carboxymethyllysine (CML), an
advanced glycation end product.
In addition, sugar combines with proteins and fats in the body to produce substances called
advanced glycation end products, or AGEs) that are associated with more rapid aging of cells, increased inflammation and free-radical production, and higher risk for cancer, heart disease, and diabetes.
When glycation occurs it produces what are aptly known as AGEs, or
advanced glycation end products.
Objectives: In this study, we aimed to evaluate the plasma levels of a soluble receptor for
advanced glycation end products (sRAGE) in patients with systemic lupus erythematosus (SLE) and to investigate their relationship with different clinical, laboratory, and therapeutic parameters.
Advanced glycation end products (AGE) are heterogeneous group of compounds that are formed in a complex and sequential non-enzymatic reactions, collectively called the Maillard reaction [1,2].
Results: The increase in glycation was observed from 1st to 3rd week of incubation, while it decreased after the 5th week due to the formation of
advanced glycation end products.
